PHARMACY

Health Mart launches national ‘Power Your Partnerships’ series

BY Sandra Levy

Health Mart is offering independent pharmacies practical advice for creating and maintaining prescriber relationships to improve patient outcomes and grow their businesses through its sixth annual Town Hall and continuing education series titled Power Your Partnerships.

The pharmacist-led series will supply pharmacists, pharmacy technicians and pharmacy owners with the tools to develop patient and prescriber relationships that strengthen their pharmacy’s impact. Health Mart will host more than 80 events across the country through early 2019.

The Power Your Partnerships event features one of 19 successful Health Mart owners leading an interactive CE session outlining collaboration benefits and discussing the influence independent pharmacies can have on prescriber performance measures.

Pharmacist facilitators will share ideas for developing a clear communication strategy, including how to access prescribers, and how to determine their needs and anticipate questions. Building on success stories of becoming a trusted prescriber partner, attendees will receive a 30-day action plan with next steps and resources to successfully create and maintain prescriber relationships that drive results in their pharmacy, Health Mart said.

“For independent pharmacists looking to grow their business, the Power Your Partnerships event provides key knowledge and resources to hit the ground running with prescriber partnerships. As the shift to true performance-based reimbursement accelerates, more patients are in these advanced payment programs,” chief operations officer for Thrive Pharmacy Solutions and Power Your Partnerships instructor, John Gregg said. “This has had a major impact on physicians as they face increasing scrutiny on clinical and cost metrics. As a result, prescribers are looking for partners to help them in that process. These partnerships aren’t happening on a large scale yet, so this is a substantial opportunity for independent pharmacists.”

“The changing landscape from fee-for-service to value-based reimbursement opens new windows of opportunity for pharmacists who are willing to adapt and embrace these changes,” Bartle’s Pharmacy owner, class facilitator and 2018 McKesson Pharmacy of the Year winner, Heather Ferrarese said. “Town Hall meetings are a great way to network with your peers to help find solutions to problems and stay current with the latest trends.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Lupin receives FDA nod for generic Mepron

BY Sandra Levy

Lupin has received the Food and Drug Administration’s clearance for atovaquone oral suspension in a 750 mg/5 mL dosage strength.

The product is a generic version of GlaxoSmithKline’s Mepron oral suspension, 750 mg/5 mL.

Atovaquone oral suspension is indicated for prevention and acute oral treatment of mild-to moderate pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole.

The product has a market value of approximately $117.4 million, according to June 2018 IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Amneal gets FDA approval for two generics

BY Sandra Levy

Amneal Pharmaceuticals has received the Food and Drug Administration’s blessing for chlorpromazine hydrochloride tablets in 10 mg, 25 mg, 50 mg, 100 mg and 200 mg dosage strengths.

Chlorpromazine hydrochloride tablets had a market value of approximately $207 million for the 12 months ended July 2018, according to IQVIA.

“Our large and diversified generic pipeline continues to deliver an industry leading number of approvals and launches in 2018,” Amneal president and CEO Rob Stewart, said. “The immediate launch of chlorpromazine hydrochloride tablets, a potentially high-value opportunity, further enhances our generic portfolio and our commitment to provide patients with a more affordable treatment option.”

In a separate development, Amneal also received the FDA’s nod for a generic version of methergine tablets, 0.2 mg (methylergonovine maleate tablet, 0.2 mg ).

Methylergonovine maleate tablets had a market value of approximately $73 million for the 12 months ending July 2018, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?